Thromboprophylaxis in Patients With COVID-19
SurgeryPage Navigation
BACKGROUND
Hospitalized patients of COVID-19 are often observed to have biomarkers of hypercoagulable state with an increased chance of incidence of VTE. In response to this, CHEST issued a rapid clinical guidance for prevention of VTE by incorporating the improved evidence updated in the past 18 months.
STUDY DESIGN AND METHODS
The research focused on the question of finding the optimal approach to thromboprophylaxis in hospitalized patients. To obtain the answers MEDLINE is searched and eight randomized controlled trials and one observational study were included in the study and a meta-analysis was performed. The panel created summaries using the GRADE Evidence-to-Decision framework. Updated guidance statements were drafted, and a modified Delphi approach was used for obtaining consensus.
RESULTS
Separate guidance statements are provided for VTE prevention in hospitalized patients with acute (moderate) illness and critically ill patients in the ICU. Each of the original questions and recommendations are divided into two questions: standard prophylaxis vs therapeutic (or escalated dose) prophylaxis and standard prophylaxis vs intermediate dose prophylaxis. As a result three additional recommendations are obtained based upon higher quality evidence.
CONCLUSION
Advances in care for patients with COVID-19 have improved overall outcomes. However, incidence of VTE in those patients remains elevated. It has been recommended to provide standard thromboprophylaxis for VTE in critically ill patients, and moderately ill patients with a low bleeding risk might benefit from therapeutic heparin.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer
2.
GLP-1 receptor agonists show anti-cancer benefits beyond weight loss
3.
MGRS Relapse-Free Survival Better With Maintenance Therapy
4.
New protein target discovered for childhood medulloblastomas
5.
The pancreatic ductal adenocarcinoma mRNA vaccine holds promise for preventing relapse.
1.
Essential Updates in Hematology in Daily Practice
2.
Engineering the Future of Oncology with CAR- Natural Killer Cell Design & Therapeutics
3.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
4.
Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer
5.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
1.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Symposium on Oncology, Cardiology and Critical Care Innovations
4.
International Conference on Cancer Nursing and Hematology Support
5.
International Conference on Clinical Medicine and Surgical Care
1.
Understanding Common Causes of Abnormal Blood Counts
2.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
3.
Understanding Blood Disorders and Their Diagnosis
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge